Analysts Set Akero Therapeutics, Inc. (NASDAQ:AKRO) PT at $41.13

Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) have been given a consensus rating of “Moderate Buy” by the nine research firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $41.13.

A number of equities analysts recently issued reports on the company. HC Wainwright restated a “buy” rating and issued a $50.00 price target on shares of Akero Therapeutics in a research report on Tuesday, June 11th. Cantor Fitzgerald restated an “overweight” rating on shares of Akero Therapeutics in a research note on Thursday, June 20th. Wolfe Research began coverage on shares of Akero Therapeutics in a research report on Tuesday, June 11th. They issued an “outperform” rating on the stock. Bank of America initiated coverage on shares of Akero Therapeutics in a research report on Monday, April 22nd. They set a “neutral” rating and a $30.00 price objective for the company. Finally, Canaccord Genuity Group dropped their price target on shares of Akero Therapeutics from $59.00 to $56.00 and set a “buy” rating on the stock in a research note on Monday, May 13th.

Insider Transactions at Akero Therapeutics

In other Akero Therapeutics news, COO Jonathan Young sold 5,000 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $26.75, for a total value of $133,750.00. Following the sale, the chief operating officer now owns 241,854 shares of the company’s stock, valued at $6,469,594.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Andrew Cheng sold 7,894 shares of the firm’s stock in a transaction that occurred on Tuesday, June 11th. The shares were sold at an average price of $22.64, for a total transaction of $178,720.16. Following the sale, the chief executive officer now owns 581,553 shares in the company, valued at $13,166,359.92. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Jonathan Young sold 5,000 shares of the stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $26.75, for a total value of $133,750.00. Following the transaction, the chief operating officer now directly owns 241,854 shares in the company, valued at approximately $6,469,594.50. The disclosure for this sale can be found here. Insiders sold 205,529 shares of company stock valued at $5,452,376 in the last 90 days. 7.94% of the stock is currently owned by insiders.

Institutional Trading of Akero Therapeutics

A number of hedge funds have recently added to or reduced their stakes in AKRO. Headlands Technologies LLC purchased a new position in shares of Akero Therapeutics in the 4th quarter valued at $28,000. Russell Investments Group Ltd. increased its position in shares of Akero Therapeutics by 2,366.0% in the 1st quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company’s stock worth $31,000 after purchasing an additional 1,183 shares during the last quarter. Quarry LP grew its position in shares of Akero Therapeutics by 40.0% in the 4th quarter. Quarry LP now owns 1,750 shares of the company’s stock worth $41,000 after acquiring an additional 500 shares in the last quarter. Strs Ohio lifted its position in shares of Akero Therapeutics by 100.0% in the 4th quarter. Strs Ohio now owns 2,000 shares of the company’s stock worth $46,000 after buying an additional 1,000 shares during the last quarter. Finally, Quest Partners LLC bought a new position in shares of Akero Therapeutics during the fourth quarter valued at approximately $75,000.

Akero Therapeutics Stock Performance

Shares of AKRO stock opened at $25.17 on Monday. The stock’s 50-day moving average is $23.65 and its two-hundred day moving average is $23.12. The company has a debt-to-equity ratio of 0.04, a quick ratio of 30.12 and a current ratio of 30.12. Akero Therapeutics has a 1 year low of $11.25 and a 1 year high of $53.77. The firm has a market cap of $1.74 billion, a price-to-earnings ratio of -7.87 and a beta of -0.28.

Akero Therapeutics (NASDAQ:AKRO) last announced its earnings results on Friday, May 10th. The company reported ($0.90) EPS for the quarter, meeting analysts’ consensus estimates of ($0.90). Analysts predict that Akero Therapeutics will post -3.82 earnings per share for the current year.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.